Effectiveness and Tolerance of Neoadjuvant Chemotherapy for Treatment of Locally Advanced Gastric Cancer
Authors: Van Tu Dao , Khac Dung Nguyen , Thi Ha Nguyen , Thi Thu Hien Tran , Thi Phuong Lan Nguyen 
Published: July 2022

This study aims to assess effectiveness and tolerance with neoadjuvant chemotherapy in patients with locally advanced gastric cancer in the period of 2018-2020. The study used the descriptive cross-sectional method to investigate 70 patients diagnosed with locally advanced gastric cancer, assigned to ECX/ECF or FLOT neoadjuvant chemotherapy regimens at Vietnam National Cancer Hospital. The results show that the partial response rates in the ECX/ECF and FLOT groups were 69.70% and 89.20%, respectively. There was no significant difference in the response level between the two groups (p = 0.716). 78.79% in the ECX/ECF group and 88.56% in the FLOT group underwent surgery. Neutropenia was an adverse event with the highest rate of grades 3 and 4 in both regimens (FLOT regimen was 10.81%, ECX/ECF regimen was 24.24%). There is a statistically significant difference in the incidence of events between the groups with prophylaxis and non-prophylaxis by granulocyte colony-stimulating factor. Taken together, there was no significant difference in the response level between the two groups; regarding the event of neutropenia, it could be controlled by prophylaxis in terms of benefits and risks for each patient.

Keywords:

Gastric cancer, effectiveness, safety, neoadjuvant chemotherapy.

References

[1] International Agency for Research on Cancer Global Cancer Observatory, 2020.[2] Ministry of Health, Guidelines for the Diagnosis and Treatment of Stomach Cancer, 2020 (in Vietnamese).[3] K. Liu, G. Li, C. Fan, C. Zhou, J. Li, Adapted Choi response Criteria for Prediction of Clinical Outcome in Locally Advanced Gastric Cancer Patients Following Preoperative Chemotherapy, Acta Radiologica, Vol. 53, No. 2, 2012, pp.127-34, https:// doi.org/10.1258/ar.2011.110273.[4] D. Cunningham, W. H. Allum, S. P. Stenning,J. N. Thompson, C. J. H. V. Velde, M. Nicolson,J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson,D. B. Smith, R. E. Langley, M. Verma, S. Weeden,Y. J. Chua, MAGIC Trial Participants. Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer, New England Journal of Medicine, Vol. 355, No.1, 2006, pp. 11-20, https://doi.org/10.1056/ NEJMoa055531.[5] S. E. A. Batran, N. Homann, C. Pauligk,T. O. Goetze, J. Meiler, S. Kasper, H. G. Koppet, et al., FLOT4-AIO Investigators, Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial, Lancet, Vol. 393, No. 10184, 2019, pp. 1948-1957, https://doi.org/ 10.1016/S0140-6736(18)32557-1.[6] L. Sung, P. C. Nathan, S. M. Alibhai, G. A. Tomlinson, J. Beyene, Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection, Annals of Internal Medicine, Vol. 147, No. 6, 2007, pp. 400-411, https://doi.org/10.7326/0003 - 4819 - 147 - 6-200709180 - 00010.